Perivascular adipose tissue from human systemic and coronary vessels

The emergence of a new pharmacotherapeutic target

Reza Aghamohammadzadeh, Sarah Withers, Fiona Lynch, Adam Greenstein, Rayaz Malik, Anthony Heagerty

Research output: Contribution to journalReview article

57 Citations (Scopus)

Abstract

Fat cells or adipocytes are distributed ubiquitously throughout the body and are often regarded purely as energy stores. However, recently it has become clear that these adipocytes are engine rooms producing large numbers of metabolically active substances with both endocrine and paracrine actions. White adipocytes surround almost every blood vessel in the human body and are collectively termed perivascular adipose tissue (PVAT). It is now well recognized that PVAT not only provides mechanical support for any blood vessels it invests, but also secretes vasoactive and metabolically essential cytokines known as adipokines, which regulate vascular function. The emergence of obesity as a major challenge to our healthcare systems has contributed to the growing interest in adipocyte dysfunction with a view to discovering new pharmacotherapeutic agents to help rescue compromised PVAT function. Very few PVAT studies have been carried out on human tissue. This review will discuss these and the hypotheses generated from such research, as well as highlight the most significant and clinically relevant animal studies showing the most pharmacological promise. Linked Articles This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit

Original languageEnglish
Pages (from-to)670-682
Number of pages13
JournalBritish Journal of Pharmacology
Volume165
Issue number3
DOIs
Publication statusPublished - Feb 2012
Externally publishedYes

Fingerprint

Adipocytes
Blood Vessels
Adipose Tissue
Coronary Vessels
White Adipocytes
Adipokines
Human Body
Obesity
Fats
Pharmacology
Cytokines
Delivery of Health Care
Research

Keywords

  • adipocytes
  • adipokines
  • adiponectin
  • coronary vessels
  • epicardial adipose tissue
  • leptin
  • metabolic syndrome
  • obesity
  • perivascular adipose tissue
  • PVAT

ASJC Scopus subject areas

  • Pharmacology

Cite this

Perivascular adipose tissue from human systemic and coronary vessels : The emergence of a new pharmacotherapeutic target. / Aghamohammadzadeh, Reza; Withers, Sarah; Lynch, Fiona; Greenstein, Adam; Malik, Rayaz; Heagerty, Anthony.

In: British Journal of Pharmacology, Vol. 165, No. 3, 02.2012, p. 670-682.

Research output: Contribution to journalReview article

Aghamohammadzadeh, Reza ; Withers, Sarah ; Lynch, Fiona ; Greenstein, Adam ; Malik, Rayaz ; Heagerty, Anthony. / Perivascular adipose tissue from human systemic and coronary vessels : The emergence of a new pharmacotherapeutic target. In: British Journal of Pharmacology. 2012 ; Vol. 165, No. 3. pp. 670-682.
@article{fbcd9fe0305a43f8be24e95dd6bb894f,
title = "Perivascular adipose tissue from human systemic and coronary vessels: The emergence of a new pharmacotherapeutic target",
abstract = "Fat cells or adipocytes are distributed ubiquitously throughout the body and are often regarded purely as energy stores. However, recently it has become clear that these adipocytes are engine rooms producing large numbers of metabolically active substances with both endocrine and paracrine actions. White adipocytes surround almost every blood vessel in the human body and are collectively termed perivascular adipose tissue (PVAT). It is now well recognized that PVAT not only provides mechanical support for any blood vessels it invests, but also secretes vasoactive and metabolically essential cytokines known as adipokines, which regulate vascular function. The emergence of obesity as a major challenge to our healthcare systems has contributed to the growing interest in adipocyte dysfunction with a view to discovering new pharmacotherapeutic agents to help rescue compromised PVAT function. Very few PVAT studies have been carried out on human tissue. This review will discuss these and the hypotheses generated from such research, as well as highlight the most significant and clinically relevant animal studies showing the most pharmacological promise. Linked Articles This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit",
keywords = "adipocytes, adipokines, adiponectin, coronary vessels, epicardial adipose tissue, leptin, metabolic syndrome, obesity, perivascular adipose tissue, PVAT",
author = "Reza Aghamohammadzadeh and Sarah Withers and Fiona Lynch and Adam Greenstein and Rayaz Malik and Anthony Heagerty",
year = "2012",
month = "2",
doi = "10.1111/j.1476-5381.2011.01479.x",
language = "English",
volume = "165",
pages = "670--682",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Perivascular adipose tissue from human systemic and coronary vessels

T2 - The emergence of a new pharmacotherapeutic target

AU - Aghamohammadzadeh, Reza

AU - Withers, Sarah

AU - Lynch, Fiona

AU - Greenstein, Adam

AU - Malik, Rayaz

AU - Heagerty, Anthony

PY - 2012/2

Y1 - 2012/2

N2 - Fat cells or adipocytes are distributed ubiquitously throughout the body and are often regarded purely as energy stores. However, recently it has become clear that these adipocytes are engine rooms producing large numbers of metabolically active substances with both endocrine and paracrine actions. White adipocytes surround almost every blood vessel in the human body and are collectively termed perivascular adipose tissue (PVAT). It is now well recognized that PVAT not only provides mechanical support for any blood vessels it invests, but also secretes vasoactive and metabolically essential cytokines known as adipokines, which regulate vascular function. The emergence of obesity as a major challenge to our healthcare systems has contributed to the growing interest in adipocyte dysfunction with a view to discovering new pharmacotherapeutic agents to help rescue compromised PVAT function. Very few PVAT studies have been carried out on human tissue. This review will discuss these and the hypotheses generated from such research, as well as highlight the most significant and clinically relevant animal studies showing the most pharmacological promise. Linked Articles This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit

AB - Fat cells or adipocytes are distributed ubiquitously throughout the body and are often regarded purely as energy stores. However, recently it has become clear that these adipocytes are engine rooms producing large numbers of metabolically active substances with both endocrine and paracrine actions. White adipocytes surround almost every blood vessel in the human body and are collectively termed perivascular adipose tissue (PVAT). It is now well recognized that PVAT not only provides mechanical support for any blood vessels it invests, but also secretes vasoactive and metabolically essential cytokines known as adipokines, which regulate vascular function. The emergence of obesity as a major challenge to our healthcare systems has contributed to the growing interest in adipocyte dysfunction with a view to discovering new pharmacotherapeutic agents to help rescue compromised PVAT function. Very few PVAT studies have been carried out on human tissue. This review will discuss these and the hypotheses generated from such research, as well as highlight the most significant and clinically relevant animal studies showing the most pharmacological promise. Linked Articles This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit

KW - adipocytes

KW - adipokines

KW - adiponectin

KW - coronary vessels

KW - epicardial adipose tissue

KW - leptin

KW - metabolic syndrome

KW - obesity

KW - perivascular adipose tissue

KW - PVAT

UR - http://www.scopus.com/inward/record.url?scp=84855666957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855666957&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01479.x

DO - 10.1111/j.1476-5381.2011.01479.x

M3 - Review article

VL - 165

SP - 670

EP - 682

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 3

ER -